Duncan Walker

2.0k total citations
38 papers, 1.1k citations indexed

About

Duncan Walker is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Duncan Walker has authored 38 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Molecular Biology, 14 papers in Oncology and 12 papers in Hematology. Recurrent topics in Duncan Walker's work include Protein Degradation and Inhibitors (14 papers), Ubiquitin and proteasome pathways (13 papers) and Multiple Myeloma Research and Treatments (12 papers). Duncan Walker is often cited by papers focused on Protein Degradation and Inhibitors (14 papers), Ubiquitin and proteasome pathways (13 papers) and Multiple Myeloma Research and Treatments (12 papers). Duncan Walker collaborates with scholars based in United States, Switzerland and United Kingdom. Duncan Walker's co-authors include James L. Maller, Brian Tunquist, Linda J. Pike, Stephen Dalton, Simon J. Conn, Renate Faast, Peter D. Rathjen, Joy Rathjen, Sherilyn Goldstone and Richard Woessner and has published in prestigious journals such as Nature, Blood and Biochemistry.

In The Last Decade

Duncan Walker

37 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Duncan Walker United States 12 879 339 289 200 98 38 1.1k
Adam Shutes United States 16 847 1.0× 186 0.5× 312 1.1× 92 0.5× 104 1.1× 19 1.2k
Deborah H. Brotherton United Kingdom 11 998 1.1× 396 1.2× 231 0.8× 193 1.0× 100 1.0× 20 1.2k
Richard Woessner United States 20 1.2k 1.4× 738 2.2× 176 0.6× 183 0.9× 103 1.1× 45 1.6k
Chris R. Evelyn United States 13 777 0.9× 183 0.5× 245 0.8× 67 0.3× 63 0.6× 14 1.0k
Anita Diu‐Hercend United States 8 715 0.8× 444 1.3× 583 2.0× 115 0.6× 79 0.8× 10 1.1k
Sean Caenepeel United States 16 817 0.9× 433 1.3× 108 0.4× 120 0.6× 145 1.5× 22 1.3k
Zhi-Min Yuan United States 16 938 1.1× 606 1.8× 395 1.4× 104 0.5× 220 2.2× 20 1.3k
Joan MacNeill United States 6 841 1.0× 303 0.9× 123 0.4× 111 0.6× 135 1.4× 6 1.1k
Linda S. Mulcahy United States 11 1.1k 1.2× 492 1.5× 144 0.5× 256 1.3× 112 1.1× 13 1.7k

Countries citing papers authored by Duncan Walker

Since Specialization
Citations

This map shows the geographic impact of Duncan Walker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Duncan Walker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Duncan Walker more than expected).

Fields of papers citing papers by Duncan Walker

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Duncan Walker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Duncan Walker. The network helps show where Duncan Walker may publish in the future.

Co-authorship network of co-authors of Duncan Walker

This figure shows the co-authorship network connecting the top 25 collaborators of Duncan Walker. A scholar is included among the top collaborators of Duncan Walker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Duncan Walker. Duncan Walker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Caravella, Justin A., R. Bruce Diebold, Anna Ericsson, et al.. (2020). Structure-Based Design and Identification of FT-2102 (Olutasidenib), a Potent Mutant-Selective IDH1 Inhibitor. Journal of Medicinal Chemistry. 63(4). 1612–1623. 111 indexed citations
3.
Rong, Haojing, Kirti Sharma, Bin Yang, et al.. (2020). Mechanisms of the Anti-Tumor Activity of STAT3 Degraders in Lymphoma. Blood. 136(Supplement 1). 42–42.
4.
Gehrmann, T., Xuan Chen, Juan Cruz–Martinez, et al.. (2018). Jet cross sections and transverse momentume distributions with NNLOJET. Zurich Open Repository and Archive (University of Zurich). 74–74. 11 indexed citations
5.
Walker, Duncan, E. W. N. Glover, Alexander Huss, T. Gehrmann, & A. Gehrmann–De Ridder. (2018). NNLO QCD Corrections to W+jet Production in NNLO JET. Zurich Open Repository and Archive (University of Zurich). 41–41. 2 indexed citations
6.
Shah, Jatin J., Jonathan L. Kaufman, Jeffrey A. Zonder, et al.. (2017). A Phase 1 and 2 study of Filanesib alone and in combination with low‐dose dexamethasone in relapsed/refractory multiple myeloma. Cancer. 123(23). 4617–4630. 48 indexed citations
7.
8.
Shah, Jatin J., Jeffrey A. Zonder, Adam D. Cohen, et al.. (2011). ARRY-520 Shows Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma in a Phase 1 Dose-Escalation Study. Blood. 118(21). 1860–1860. 9 indexed citations
9.
Tunquist, Brian, Richard Woessner, & Duncan Walker. (2010). Mcl-1 Stability Determines Mitotic Cell Fate of Human Multiple Myeloma Tumor Cells Treated with the Kinesin Spindle Protein Inhibitor ARRY-520. Molecular Cancer Therapeutics. 9(7). 2046–2056. 58 indexed citations
10.
Conroy, Andrew, David E. Stockett, Duncan Walker, et al.. (2009). SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples. Cancer Chemotherapy and Pharmacology. 64(4). 723–732. 106 indexed citations
11.
Woessner, Richard, Brian Tunquist, Christine Lemieux, et al.. (2009). ARRY-520, a novel KSP inhibitor with potent activity in hematological and taxane-resistant tumor models.. PubMed. 29(11). 4373–80. 51 indexed citations
12.
Choong, Ingrid, Iana M. Serafimova, David E. Stockett, et al.. (2008). A diaminocyclohexyl analog of SNS-032 with improved permeability and bioavailability properties. Bioorganic & Medicinal Chemistry Letters. 18(21). 5763–5765. 10 indexed citations
13.
Fahr, Bruce J., David E. Stockett, Sravanthi Cheeti, et al.. (2008). Modifications of the isonipecotic acid fragment of SNS-032: Analogs with improved permeability and lower efflux ratio. Bioorganic & Medicinal Chemistry Letters. 18(23). 6236–6239. 5 indexed citations
14.
Hyde, Jennifer, et al.. (2006). SNS-032 is a potent and selective inhibitor of CDK2, 7 and 9 and induces cell death by inhibiting cell cycle progression and the expression of antiapoptotic proteins. Cancer Research. 66. 491–491. 7 indexed citations
15.
Hyde, Jennifer, et al.. (2005). The phase I clinical compound SNS-595 acts during S-phase and causes a sustained G2 arrest. Cancer Research. 65. 538–538. 1 indexed citations
16.
Faast, Renate, Simon J. Conn, Sherilyn Goldstone, et al.. (2002). Pluripotent cell division cycles are driven by ectopic Cdk2, cyclin A/E and E2F activities. Oncogene. 21(54). 8320–8333. 295 indexed citations
17.
Walker, Duncan & James L. Maller. (1991). Role for cyclin A in the dependence of mitosis on completion of DMA replication. Nature. 354(6351). 314–317. 178 indexed citations
18.
Walker, Duncan & Linda J. Pike. (1990). Stimulation of purified phosphatidylinositol 4-kinase by cobra venom cardiotoxin. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1055(3). 295–298. 10 indexed citations
19.
Walker, Duncan, Nancy Dougherty, & Linda J. Pike. (1988). Purification and characterization of a phosphatidylinositol kinase from A431 cells. Biochemistry. 27(17). 6504–6511. 61 indexed citations
20.
Walker, Duncan, et al.. (1987). Substrate specificity and kinetic mechanism of human placental insulin receptor/kinase. Biochemistry. 26(5). 1428–1433. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Adam Shutes Breakdown of academic impact, for papers by Deborah H. Brotherton Breakdown of academic impact, for papers by Richard Woessner Breakdown of academic impact, for papers by Chris R. Evelyn Breakdown of academic impact, for papers by Anita Diu‐Hercend Breakdown of academic impact, for papers by Sean Caenepeel Breakdown of academic impact, for papers by Zhi-Min Yuan Breakdown of academic impact, for papers by Joan MacNeill Breakdown of academic impact, for papers by Linda S. Mulcahy
Rankless by CCL
2026